Deal Size Increased to $124M in Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
The deal size was increased to $124M in common stock from $85M in common stock. Wells Fargo and Mizuho acted as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXGN
Wall Street analysts forecast AXGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 37.67 USD with a low forecast of 34.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.850
Low
34.00
Averages
37.67
High
40.00
Current: 34.850
Low
34.00
Averages
37.67
High
40.00
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axogen Prices Upsized Public Offering of 4 Million Shares at $31 Each, Raising Approximately $124 Million
- Financing Plan: Axogen priced its upsized public offering of 4 million shares at $31 each on Wednesday, expected to generate approximately $124 million in gross proceeds, which will be used for early loan repayment, working capital, and other general corporate purposes, thereby strengthening the company's financial position and supporting future growth initiatives.
- Stock Performance: Axogen shares fell 2.21% to $32.28 on Thursday, approaching its 52-week high of $34.70, reflecting a 74.75% increase in stock price over the past 12 months, indicating strong market recognition of the company's long-term growth potential.
- Technical Indicators: The stock is currently trading 9.8% below its 20-day simple moving average but 31.4% above its 100-day simple moving average, suggesting some short-term downward pressure while maintaining a positive long-term trend, with an RSI of 59.14 indicating a neutral state.
- Analyst Ratings: The stock carries a Buy rating with an average price target of $27.79, with Canaccord Genuity, HC Wainwright & Co., and Jefferies raising their targets to $37.00, $39.00, and $36.00 respectively, reflecting analysts' optimistic outlook on its future performance.
Continue Reading
Axogen (AXGN) Prices Upsized Offering of 4 Million Shares at $31, Raising Approximately $124 Million
- Stock Offering: Axogen has announced an upsized public offering of 4 million shares at $31 each, raising approximately $124 million, although this news has led to a nearly 5% decline in premarket trading.
- Use of Proceeds: The company intends to utilize the net proceeds for early repayment of its term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes, thereby optimizing its financial structure and enhancing liquidity.
- Underwriter Arrangement: Wells Fargo Securities and Mizuho are acting as lead book-running managers for the offering, ensuring a smooth financing process and boosting market confidence.
- Stock Price Fluctuation: AXGN has traded within a range of $9.22 to $34.71 over the past year, closing at $33.01 on Wednesday, up 3.58% from the previous day, indicating market interest in the company's future prospects.
Continue Reading